600–1,200 mg/day as a supplement; higher doses in clinical uses.
Reduces repetitive behaviors.
View the study (systematic review) →As a mucolytic, it reduces exacerbations.
View the study (systematic review) →2,400–3,000 mg/day in resistant OCD: reduces Y-BOCS scores by 15–25% as an adjunct to SSRIs.
View the study (RCT) →Possible improvement in PCOS and semen parameters.
View the study (systematic review) →As a glutathione precursor and glutamate modulator, it shows an anxiolytic signal in psychiatric patients. Small effect but an excellent safety profile.
View the study (systematic review) →⏱ 3 min read
N-acetylcysteine, known in all clinical contexts as NAC, is a derivative of the amino acid cysteine to which an acetyl group is added, giving it greater stability and better oral bioavailability; its most important biological utility is that it serves as a direct precursor of glutathione, the main endogenous antioxidant produced by the body's cells and the molecule on which a good part of our capacity to neutralize free radicals and conjugate toxins in the liver rests.
NAC has a curious clinical profile because it is at once a drug with a formal indication (a mucolytic for respiratory diseases and an antidote for acetaminophen poisoning) and a widely researched supplement in psychiatry, hepatology, and respiratory medicine; this dual identity gives it an unusual solidity of evidence compared with other supplements whose profile is usually based on much more modest studies.
The clearest and best-established clinical indication of NAC is acute acetaminophen poisoning, where its intravenous or oral administration within the first 8 to 24 hours after the overdose prevents the massive liver damage that metabolized acetaminophen can cause by depleting hepatic glutathione stores; this use is a hospital emergency and has saved countless lives since its introduction in the 1970s.
The mechanism is elegant: NAC replenishes glutathione, allowing the toxic metabolite of acetaminophen (NAPQI) to be conjugated before it binds covalently to liver proteins and causes necrosis; it is one of the antidotes with the best evidence in emergency medicine and an example of how understanding the biochemistry of a poison makes it possible to design precise and effective therapies.
As a mucolytic, NAC has a long history of use in COPD and chronic bronchitis with thick mucus production: it breaks the disulfide bridges of mucoproteins, thinning bronchial secretions and making them easier to expectorate; several meta-analyses have shown that doses of 600 to 1,200 milligrams daily reduce COPD exacerbations in people with chronic bronchitis, especially when treatment is maintained for months.
The effect is modest but clinically significant, especially in people who have more than two exacerbations a year, where reducing that frequency can translate into better quality of life, fewer hospital visits, and a better long-term prognosis; the cost is low and the safety profile is excellent, which makes it a very reasonable intervention as an adjunct to standard inhaled treatment.
One of the most interesting lines of research on NAC in the last decade is its use in compulsive disorders such as trichotillomania, excoriation disorder (pathological skin picking), and some conditions on the obsessive-compulsive spectrum, where several randomized trials have shown significant improvements with doses of 1,200 to 2,400 milligrams daily for 12 weeks, an indication that conventional psychiatry treats poorly with many medications.
It has also been investigated in addictions (cocaine, cannabis, pathological gambling) with modest but encouraging results, in bipolar depression as an adjunct to mood stabilizers, and in schizophrenia to reduce negative symptoms, all lines with limited but methodologically serious data that justify active clinical follow-up of this molecule in psychiatry.
In chronic liver disease not associated with acetaminophen, NAC improves some biochemical markers but does not robustly change the clinical prognosis; in PCOS (polycystic ovary syndrome) with insulin resistance, several trials have shown improvements in metabolic and reproductive parameters comparable to metformin; in male fertility, it improves sperm quality parameters in men with idiopathic problems when combined with other antioxidants.
The doses studied range from 600 to 2,400 milligrams daily, divided into two or three doses, ideally on an empty stomach to improve absorption, although it can be taken with food if it causes digestive discomfort; clinical effects appear within days for respiratory function and within weeks or months for psychiatric or chronic indications; NAC has a characteristic sulfurous smell that some people find unpleasant.
It is generally well tolerated; the most frequent adverse effects are gastrointestinal discomfort, a bad taste in the mouth, and, on rare occasions, cutaneous hypersensitivity reactions; people taking nitrates or anticoagulants should be cautious because of possible potentiation of the effect; prolonged use at high doses in people with asthma can worsen bronchospasm in some sensitive cases, a precaution that warrants medical consultation before starting.
Information, not medical advice. Scientific evidence reflects the quality of the studies.